NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018

J Natl Compr Canc Netw. 2018 Jul;16(7):807-821. doi: 10.6004/jnccn.2018.0062.

Abstract

The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the targeted therapy and immunotherapy sections in the NCCN Guidelines. For the 2018 update, a new section on biomarkers was added.

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Immunological / pharmacology
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / genetics
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / immunology
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Disease Progression
  • Drug Resistance, Neoplasm / genetics
  • Drug Resistance, Neoplasm / immunology
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / immunology
  • Lung Neoplasms / mortality
  • Medical Oncology / standards
  • Molecular Targeted Therapy / methods
  • Molecular Targeted Therapy / standards*
  • Mutation
  • Progression-Free Survival
  • Randomized Controlled Trials as Topic
  • Societies, Medical / standards
  • United States

Substances

  • Antineoplastic Agents, Immunological
  • Biomarkers, Tumor